Navigation Links
NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
Date:10/29/2009

ROCKVILLE, Md., Oct. 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Oppenheimer 20th Annual Healthcare Conference. Dr. Singhvi's presentation will take place at 3:20 pm local time on November 3, 2009 at the Waldorf=Astoria, New York, NY. Dr. Singhvi will provide an overview of the company's business strategy and research and development progress. A link to the live presentation can be accessed via the Company website at www.novavax.com under the Investors tab. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

About the Oppenheimer 20th Annual Healthcare Conference

The Oppenheimer 20th Annual Healthcare Conference will take place at the Waldorf=Astoria in New York City, November 3-4, 2009. This conference will present a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries. Over 19 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in this sector. Through formal company presentations and panels, attendees will gain insight from, and access to, industry leaders.

The Companies participating in this conference will address topical issues such as health reform, Medicare and Medicaid, generic drug regulation, development of new blockbuster pharmaceutical and biotechnology products, product safety and patent issues, cross-border reimportation, Food and Drug Administration policy, managed care, and the current M&A environment.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
2. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
3. Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
4. Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
5. Novavax Announces Board of Director Changes
6. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
7. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
8. Novavax Reports Second Quarter 2009 Financial Results
9. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
10. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
11. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage ... its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats ... sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the ...
(Date:10/11/2017)... ... 11, 2017 , ... Personal eye wash is a basic first aid supply for any work ... which eye do you rinse first if a dangerous substance enters both eyes? It’s one ... with its unique dual eye piece. , “Whether its dirt and debris, or an ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
Breaking Biology Technology:
(Date:8/15/2017)... Aug. 15 2017   ivWatch LLC , a medical device ... therapy, today announced receipt of its ISO 13485 Certification, the global ... International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection of ... "This is an important milestone ...
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
Breaking Biology News(10 mins):